95 related articles for article (PubMed ID: 7557257)
1. The disposition of new arabinosylcytosine derivative-- 5'-chloro-5'-deoxy-arabinosylcytosine--in rats.
Novotný L; Reichelová V; Janků I; Rauko P; Ujházy V
Gen Pharmacol; 1995 Sep; 26(5):1101-5. PubMed ID: 7557257
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation and in vitro activity of an arabinosylcytosine 5'-chloro-5'-deoxy analog.
Novotný L; Reichelová V; Balázová E; Scheithauer W; Benesová M; Ujházy V
Anticancer Drugs; 1991 Oct; 2(5):495-502. PubMed ID: 1804392
[TBL] [Abstract][Full Text] [Related]
3. Transformation kinetics of the 5'-chloro-5'-deoxy analogue of arabinosylcytosine.
Stankovicová M; Novotný L; Bachratá M; Bílková J; Rauko P
Neoplasma; 1999; 46(3):161-5. PubMed ID: 10613591
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of cyclocytidine and arabinosylcytosine disposition in rats.
Novotný L; Farghali H; Janků I; Beránek J
Neoplasma; 1988; 35(6):707-14. PubMed ID: 2464769
[TBL] [Abstract][Full Text] [Related]
5. Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
Schwendener RA; Horber DH; Odermatt B; Schott H
J Cancer Res Clin Oncol; 1996; 122(2):102-8. PubMed ID: 8576276
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.
Han T; Fernandez M; Chou TC; Agarwal RP
J Cancer Res Clin Oncol; 2005 Sep; 131(9):609-16. PubMed ID: 16044347
[TBL] [Abstract][Full Text] [Related]
7. Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
Schwendener RA; Schott H
J Cancer Res Clin Oncol; 1996; 122(12):723-6. PubMed ID: 8954169
[TBL] [Abstract][Full Text] [Related]
8. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration.
Groothuis DR; Benalcazar H; Allen CV; Wise RM; Dills C; Dobrescu C; Rothholtz V; Levy RM
Brain Res; 2000 Feb; 856(1-2):281-90. PubMed ID: 10677637
[TBL] [Abstract][Full Text] [Related]
10. Antileukemic activity of sulfonamide conjugates of arabinosylcytosine.
Novotny L; Phillips OA; Rauko P; Miadokova E
Exp Oncol; 2006 Dec; 28(4):293-8. PubMed ID: 17285113
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice.
Rentsch KM; Schwendener RA; Schott H; Hänseler E
J Pharm Pharmacol; 1997 Nov; 49(11):1076-81. PubMed ID: 9401941
[TBL] [Abstract][Full Text] [Related]
12. Comparison of some biochemical parameters of arabinosylcytosine and cyclocytidine in L1210 murine leukemia cells.
Novotný L; Reichelová V; Balázová E; Ujházy V
Neoplasma; 1990; 37(1):13-22. PubMed ID: 1690864
[TBL] [Abstract][Full Text] [Related]
13. Treatment of leukemia L1210 and P388 by arabinosylcytosine-polysaccharide conjugates.
Novotný L; Balázová E; Sandula J; Ujházy V; Kéry V
Int J Cancer; 1991 Jan; 47(2):281-4. PubMed ID: 1988371
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of N-(2-hydroxyphenyl)-2-propylpentanamide in Wistar Rats and its binding properties to human serum albumin.
Correa-Basurto AM; Romero-Castro A; Correa-Basurto J; Hernández-Rodríguez M; Soriano-Ursúa MA; García-Machorro J; Tolentino-López LE; Rosales-Hernández MC; Mendieta-Wejebe JE
J Pharm Biomed Anal; 2019 Jan; 162():130-139. PubMed ID: 30236821
[TBL] [Abstract][Full Text] [Related]
15. Cytarabine conjugates with biologically active molecules and their potential anticancer activity.
Novotny L; Rauko P
Neoplasma; 2009; 56(3):177-86. PubMed ID: 19309219
[TBL] [Abstract][Full Text] [Related]
16. Preparation, properties and antileukemic activity of arabinosylcytosine polysaccharide conjugates.
Kéry V; Novotný L; Tihlárik K; Haplová J; Kacuráková M; Sandula J; Balázová E
Int J Biochem; 1990; 22(10):1203-7. PubMed ID: 2289626
[TBL] [Abstract][Full Text] [Related]
17. In vitro antileukemic activity and chemical transformation of the 5'-chloro-5'-deoxy derivative of cyclocytidine.
Stankovicová M; Rauko P; Bachratá M; Blesová M; Sveda P
Neoplasma; 1995; 42(5):255-8. PubMed ID: 8552205
[TBL] [Abstract][Full Text] [Related]
18. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
Lindner LH; Ostermann H; Hiddemann W; Kiani A; Würfel M; Illmer T; Karsch C; Platzbecker U; Ehninger G; Schleyer E
Int J Hematol; 2008 Nov; 88(4):381-386. PubMed ID: 18836794
[TBL] [Abstract][Full Text] [Related]
19. Molecular structure of a DNA decamber containing an anticancer nucleoside arabinosylcytosine: conformational perturbation by arabinosylcytosine in B-DNA.
Gao YG; van der Marel GA; van Boom JH; Wang AH
Biochemistry; 1991 Oct; 30(41):9922-31. PubMed ID: 1911784
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content.
Wright AM; Paterson AR; Sowa B; Akabutu JJ; Grundy PE; Gati WP
Br J Haematol; 2002 Mar; 116(3):528-37. PubMed ID: 11849208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
